에서 실시간으로 운영 중이에요! 자세히 알아보기

Exicure

XCUR

시가총액 US$733만

1.12 USD

0.00

0%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

1.16

+0.04

3.57%

1일

0%

5일

2.75%

1개월

-15.79%

3개월

-30.86%

6개월

-70.98%

연초 이후

-79.93%

1년

-77.14%

5년

-99.36%

10년

-99.72%

소개: Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

직원 수: 8

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 100%

부정적 0%

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties' License and Collaboration Agreement.

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

Exicure Announces Board and Committee Changes

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026.

Exicure Announces Board and Committee Changes

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 5, 2026 indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity.

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice: TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF EXICURE, INC.

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.